6.365 USD
-0.4 (-5.98%)
6.4 USD
+0.04 (+0.55%)
ChartMill assigns a Buy % Consensus number of 43% to CYCC. The Buy consensus is the weighted average rating of the current analysts ratings.
CYCC was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about CYCC.
In the previous month the buy percentage consensus was at a similar level.
CYCC was analyzed by 6 analysts. More opinions would make the average more meaningful.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-05-03 | Roth MKM | Maintains | Buy -> Buy |
| 2023-12-19 | Roth MKM | Maintains | Buy -> Buy |
| 2023-12-19 | Brookline Capital | Downgrade | Buy -> Hold |
| 2023-05-25 | Oppenheimer | Maintains | Outperform |
| 2023-03-07 | Oppenheimer | Maintains | Outperform |
| 2021-04-30 | Oppenheimer | Initiate | Outperform |
CYCLACEL PHARMACEUTICALS INC / CYCC FAQ
Can you provide the consensus rating for CYCLACEL PHARMACEUTICALS INC stock?
The consensus rating for CYCLACEL PHARMACEUTICALS INC (CYCC) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.